logo

For the Inventor, By the Inventor

Planegg, Germany

4Sc Ag


USPTO Granted Patents = 52

% Expired Patents = 53.8



Trademarks = 3

Forward Citations = 382

Loading Chart...
Loading Chart...

76 inventors (with patents filed for the assignee):

goldMedal Thomas Beckers (19 out of 36 patents)

silverMedal Thomas Maier (17 out of 45 patents)

bronzeMedal Johann Leban (12 out of 17 patents)

4.  Thomas Baer (10 out of 13 patents)

5.  Petra Gimmnich (9 out of 9 patents)

6.  Mathias Schmidt (9 out of 9 patents)

7.  Stefan Tasler (8 out of 11 patents)

8.  Volker Gekeler (8 out of 12 patents)

9.  Thomas Bär (8 out of 11 patents)

10.  Astrid Zimmermann (8 out of 15 patents)

11.  Klaus Pekari (8 out of 8 patents)

12.  Matthias Vennemann (7 out of 11 patents)

13.  Stefano Pegoraro (6 out of 6 patents)

14.  Daniel Vitt (5 out of 14 patents)

15.  Kristina Wolf (5 out of 5 patents)


Core Competencies:
HDAC Inhibitors
Kv1.3 Inhibitors
Cancer Therapy
Sulfonylpyrroles
Indolopyridines
Tetrahydropyridothiophenes
Anti-inflammatory Agents
Immunomodulatory Compounds
Proliferative Diseases
Virostatic Compounds
Phenanthridine Analogues
Heterocyclic Inhibitors

52 patents:

1. 12285410 - Combination comprising HDAC inhibitor and CD137 agonist for cancer therapy (2025-04-29),
2. 10822345 - KV1.3 inhibitors and their medical application (2020-11-03),
3. 10723743 - Kv1.3 inhibitors and their medical application (2020-07-28),
4. 10633369 - Method of inhibiting DYRK1B (2020-04-28),
5. 10399991 - Kv1.3 inhibitors and their medical applications (2019-09-03),
6. 10005769 - 2,3-dihydrobenzofuran-5YL compounds as DYRK kinase inhibitors (2018-06-26),
7. 9951050 - Method of inhibiting DYRK1B (2018-04-24),
8. 9908880 - Substituted imidazoquinolines (2018-03-06),
9. 9446040 - Substituted imidazoquinolines (2016-09-20),
10. 9073913 - Substituted imidazoquinolines (2015-07-07),
11. 8969401 - Sulfonylpyrroles (2015-03-03),
12. 8815855 - N-sulphonylpyrroles and their use as histone deacetylase inhibitors (2014-08-26),
13. 8785659 - Method for the production of sulphonylpyrroles as HDAC inhibitors (2014-07-22),
14. 8575193 - N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds (2013-11-05),
15. 8557991 - Process for preparing enantiomerically pure indolopyridines (2013-10-15),
4SC AG is a clinical-stage biopharmaceutical company focused on the development of small molecule drugs for the treatment of cancer. The company's core drug candidates target various cancer indications, including solid tumors and hematological cancers. 4SC AG utilizes its proprietary discovery platform to identify and develop potential therapeutic compounds. With a focus on personalized medicine, 4SC AG aims to provide innovative treatment options for cancer patients.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

4Sc Ag
52 Patents

#2 in Planegg

#1,018 in Germany

#13,537 in the World

Planegg, DE
Planegg, Germany

4Sc Ag

Forward Citations = 382

76 inventors:

goldMedal Thomas Beckers (19 out of 36 patents)

silverMedal Thomas Maier (17 out of 45 patents)

bronzeMedal Johann Leban (12 out of 17 patents)

4.  Thomas Baer (10 out of 13 patents)

5.  Petra Gimmnich (9 out of 9 patents)

Please report any incorrect information to [email protected]
Loading…